Papillomavirus oncoprotein E6 is a critical factor in the modulation of cervical cancer in humans. At the molecular level, formation of the E6-E6AP-p53 ternary complex, which directs p53's degradation, is the key instigator of cancer transforming properties. Herein, a Cu 2+ anthracenyl-terpyridine complex is described which specifically induces the aggregation of E6 in vitro and in cultured cells. For a hijacking mechanism, both E6 and E6AP are required for p53 ubiquitination and degradation. The Cu 2+ complex interacts with E6 at the E6AP and p53 binding sites. We show that E6 function is suppressed by aggregation, rendering it incapable of hijacking p53 and thus increasing its cellular level. Therapeutic treatments of cervical cancer are currently unavailable to infected individuals. We anticipate that this Cu 2+ complex might open up a new therapeutic avenue for the design and development of new chemical entities for the diagnosis and treatment of HPV-induced cancers.
Introduction
High-risk HPV infection is the leading cause of nearly all cases (99.7%) of cervical cancer [1] . It integrates into the host's DNA and infects the basal cells of cervix, resulting in the production of damaged and disorganized cervical cells. The concomitant loss of function leads to the development of cancer. Over 170 types of HPV are known, of which more than 40 are sexually transmitted. Around 13 high-risk types of HPV are known to cause cervical cancers [2] , with types 16 and 18 being the most prevalent, causing over 70% of cervical cancers [3] . More than 80% of women are infected with genital HPV at some point in their lives which often leads to cervical cancer [4] . Although HPV infection is widespread, its symptoms are seldom noticeable.
The genome of HPV 16 and 18 is~8 kb, which is made-up of double-stranded DNA. Of the eight different types of proteins encoded by the HPV genome, only E6 and E7 proteins exhibit cancer inducing properties. These proteins functions include immortalization of primary cell lines, activation of transmembrane signalling and alteration of the cell cycle etc. Thus, E6 and E7 are known to exhibit pleiotropic functions. Thus, E6 and E7 are considered necessary for malignant conversion. The interactions of E6 and E7 with p53 and pRB, respectively, have been suggested to be Abbreviations DLS, dynamic light scattering; FCS, fluorescence correlation spectroscopy; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IC 50 , concentration at which cells showed 50% viability; PDI, polydispersity index; tMCF-7, transfected implicated in the mechanism of inducing tumour formation [5] [6] [7] [8] [9] . The E6 protein promotes the formation of a trimeric protein complex composed of E6, p53 and the cellular ubiquitination enzyme E6AP [10, 11] . This stimulates degradation of p53 and thereby promotes unregulated cell proliferation, finally leading to increased tumour cell growth [9] . This explains why very low levels of p53 are observed in cervical carcinoma cell lines [12] . Moreover, E6 can perform its oncogenic activities without the cross-talk of p53 [13, 14] . Discovery of E6 targets is continuous, several have been identified recently. Examples include, IRF-3, E6TP1, p300/CBP, ADA3, Gps2 and hMcm7, (transcription and DNA replication regulatory proteins) and cMyc, FADD, Bak and TNF receptor 1 (apoptosis and immune evasion regulatory molecules). Besides these, E6 also targets proteins included in cell differentiation, cell-cell adhesion, epithelial cell organization, cell polarity and DNA repair [7] [8] [9] [13] [14] [15] .
Recent studies of the structure of an E6/E6AP/p53 complex suggested that ternary complex formation is required for HPV-mediated degradation of p53 [10] . The complex structure also showed that E6 forms a distinct pocket for E6AP and a cleft for p53 binding. Recent experimental evidence using pro-apoptotic peptides and small molecules highlighted that the E6AP binding pocket is druggable [16] [17] [18] . Additionally, the p53 binding cleft may represent a second potential drug binding site [10] . Therefore, HPV E6 could be an efficient drug target in order to combat cervical cancer.
Small molecules including coordination complexes are known for their antitumour activities. Cis-platin is one such example of a coordination complex. Its mechanism of action involves the formation of adducts with DNA, leading to cell death. It is also being developed as a lead molecule against amyotrophic lateral sclerosis based on its interaction with superoxide dismutase [19, 20] . Complexes with other metal ions including Cu 2+ are under intense investigation [21, 22] . Cell toxicity is well-known for copper itself, however, its complexes which exhibit several fold better responses are under consideration. Several studies have shown the antiproliferative activity of copper complexes which exhibited up to several-hundred fold better responses compared to Cu 2+ alone [21, [23] [24] [25] . Several of these organometallic complexes have been shown to exhibit antiproliferative, antimicrobial and antifungal activity by adding and incubating them to cultured media. However, the molecular mechanism behind their cytotoxicity remains elusive [26, 27] . In a structure-based drug-design, the physico-chemical nature of the molecules often render them incapable of crossing the cell wall/membrane barrier to reach their targets in a complex cellular environment, although they are quite effective binding partners under in vitro conditions [28] . Thus, small molecules which penetrate the cell and interact with crucial molecules are advantageous [29, 30] . After cell based rational screening identified a Cu 2+ complex which caused E6 to aggregate, and we have explored the molecular mechanism of action. We confirmed that this Cu 2+ complex interacts with the E6 oncoprotein and causes its aggregation inside the cells which is manifested by the formation of granular structures. Only HPV infected cells display such aggregates. Under in vitro conditions, the Cu 2+ complex binds E6 with micro-molar affinity and also with those residues forming the E6AP and p53 binding sites. Subsequent self-association forms aggregated structures under in vitro conditions similar to those observed inside the HPV-containing HeLa cells. Eventually, this led to stabilization of p53 inside the cells.
Results

Cu
2+ complex induces aggregation of isolated E6 F47R 4C/4S
Wild-type oncogenic E6 has a tendency to aggregate under isolated in vitro conditions [31, 32] . Therefore, a soluble construct of E6 (His6-MBP-tev-F47R E6 4C/ 4S) was expressed and purified via the bacterial-expression system as described previously [32] . For HPV16 E6, we purified the monomeric E6 F47R 4C/4S variant that combines the F47 ? R47 (F47R) mutation which disrupts the dimerization facilitated by the N-terminal domain with four mutations at nonconserved cysteines (C80S, C97S, C111S and C140S) preventing disulfidemediated aggregation [32] . In order to test whether the Cu 2+ complex (stable, water soluble and structurally characterized) can induce the aggregation of E6 F47R 4C/4S in isolation, the complex and ligand were coincubated for 6 h. Samples were taken out at each hour and analysed by electron microscopy. The results show that E6 F47R 4C/4S aggregates in the presence of the Cu 2+ complex under in vitro conditions and welldefined spherical structures are formed at longer times (Fig. 1A,B) . The sample, which was incubated for 6 h, was centrifuged at 35 179 g and the obtained pellet was washed with buffer and loaded onto SDS/ PAGE. The Coomassie brilliant blue-stained gel shows an intense band corresponding to monomeric E6 F47R 4C/4S and additional bands for higher oligomers (Fig. 1C) considerable decrease in fluorescence intensity. The binding of E6 F47R 4C/4S to 9-anthracene methanol yielded a K d of 4.95 mM indicating that both the Cumetal centre and the organic moiety are required for effective binding. E6 F47R 4C/4S exhibits a characteristic circular dichroism spectrum expected from the NMR/X-ray structure [10, 32] of the a/b-protein. Titration with the Cu 2+ complex showed a gradual loss of negative ellipticity at 210 and 220 nm together with a decrease at 195 nm (Fig. 2B ). This indicates that E6 F47R 4C/4S undergoes conformational changes of some secondary structure elements towards a disordered form. Again, Cu 2+ -perchlorate or 9-anthracene methanol did not induce significant conformational changes.
Cu
2+ complex induces intracellular aggregation of E6
In order to test whether the Cu 2+ complex induces the aggregation of E6 inside the cell, HPV-containing HeLa cells were coincubated. With the molecules, HPV-infected HeLa cells showed spherical aggregated structures within 2 h of incubation. Similar spherical structures were observed previously, but, their origin remains unclear [23] . These spherical structures give rise to blue fluorescence when observed under UV light (334 nm; Fig. 3A ,B). The HeLa cells showed a concentration at which cells showed 50% viability (IC 50 ) value for cell viability of 1.03 AE 0.03 lM Cu 2+ complex (Fig. 3C) . Subsequently, rational screening of cells infected with HPV (CaSki, HeLa, SiHa and ME 180) or not (HepG2, MCF7, H1229, U2OS and HEK 293) showed direct correlation of IC 50 and involvement of HPV (Fig. 3C) . Accordingly, CaSki (60-600 copies per cell), HeLa (10-50 copies per cell), SiHa (1-2 copies per cell) and ME180 (HPV-68) showed IC 50 values of 0.7 AE 0.02 lM, 1.03 AE 0.03 lM, 4.1 AE 0.7 lM, and 5.20 AE 0.4 lM, respectively. The other cell lines (non HPV-infected) showed similar toxicity against the Cu 2+ complex, with an IC 50 range between 5 and 6 lM (Fig. 3C ). Western blotting confirmed that the spherical structures are aggregated species of E6. Untreated HeLa cells showed similar levels of E6 in the soluble fraction and the cells pellet in lysed cells (Fig. 3D , lanes 1 and 2). In contrast, when the cells were treated with the Cu 2+ complex, the majority of the E6 protein was observed in the cell pelleted fraction (Fig. 3D, lanes 3 and 4) .
Although these experiments provided sufficient evidence of Cu 2+ complex-induced aggregation of E6, it is well known that wild-type E6 aggregates in isolation [31, 32] . Therefore, the pellet observed (Fig. 3D , lane 4) could be simply induced by cell opening (Fig. 3D, lane 2) . To further confirm E6 aggregation induced by the Cu 2+ complex, soluble E6 F47R 4C/ 4S was fused with GFP and subcloned into the pFLAG vector for mammalian cell expression. This construct was transiently transfected into MCF-7 cells. Note that MCF-7 cells are HPV negative and therefore contain no endogenous E6. The green fluorescence of GFP-E6 F47R 4C/4S inside MCF-7 cells when excited at 488 nm was broadly distributed throughout the cytoplasm (Fig. 3E,F) . Subsequently, these cells were coincubated with the Cu 2+ complex which, after 2 h of incubation, showed spherical aggregates inside the transfected MCF-7 cells (tMCF-7; Fig. 3G,H) . The transfected cells without Cu 2+ complex treatment showed maximum expression of GFP-E6 F47R 4C/4S in the soluble fraction (Fig. 3I , lane 1 and 2). However, most of the GFP-E6 F47R 4C/4S was seen in the pellet when transfected MCF-7 cells were coincubated with the Cu 2+ complex (Fig. 3I,  lane 3 and 4) . The transfected cells showed a threefold lower IC 50 value (1.88 AE 0.05 lM) compared to the nontransfected MCF-7 cells (5.94 AE 0.5 lM; Fig. 3C ) by the methylthiazole tetrazolium (MTT) cell viability assay. These results confirm that granular structures inside the cells are formed due to the aggregation of E6 induced by the Cu 2+ complex. Neither, Cu 2+ -perchlorate nor 9-anthracene methanol induce such spherical aggregated structures in HeLa, MCF-7, or transfected MCF-7 cells transiently expressing GFP-E6 F47R 4C/4S. p53 hijacking by E6 can be relieved by the Cu 2+ complex p53 is a transcription factor that plays a key role in regulating cell cycle progression, DNA repair and apoptosis [34] . However, p53 function is masked by E6 in HPV-infected cells (e.g. cervical cancer cells [35] ) where p53 degradation is a hallmark activity of the HPV E6 protein [6] [7] [8] [9] [10] [11] 13] . Therefore, we hypothesize that, if we could disrupt E6/E6AP/p53 complex formation e.g. by aggregating E6 in the presence of the Cu 2+ complex, p53 should not degrade and its expression will be stabilized. Western blot analyses show low expression of p53 in untreated HeLa cells as expected due to the hijacking nature of E6 (Fig. 4A, lane 1) . In doing so, E6 interacts with the LxxLL motif of E6AP, yielding the E6/E6AP heterodimer [10, 11] . This heterodimer recruits and degrades p53 via the ubiquitinmediated degradation pathways [6] [7] [8] [9] [10] [11] [12] [13] . However, in Cu 2+ complex treated cells, p53 expression is upregulated several fold (Fig. 4A, lane 2) suggesting that E6 function is suppressed, most probably by its aggregation. Also, neither E6 nor E6AP are independently capable of recruiting p53 for degradation [36, 37] . Other HPV E6 containing cell lines, i.e. CaSki, showed similar p53 stabilization when treated with the Cu 2+ complex (Fig. 4A) . Additionally, treated cervical cancer cells showed nuclear fragmentation after 48 h of incubation (Fig. 4B-G) . FACS analysis showed a 55% and 56% increase in apoptotic peak in HeLa and CaSki cells, respectively, a clear indication of apoptotic cell death induced by the Cu 2+ complex. In control MCF-7 cells lacking E6, no change in p53 expression or nuclear fragmentation after Cu 2+ complex treatment was observed (Fig. 4A,F,G) . Taken together, these results suggest that the Cu 2+ complex induces the apoptotic cell death via the p53 mediated pathway.
Next, we evaluated the residue-based interactions of the Cu 2+ complex with E6 F47R 4C/4S, which might be involved in disrupting the E6/E6AP/p53 ternary complex and/or inducing aggregation, by NMR spectroscopy [38] [39] [40] [41] [42] . The recent E6 F47R 4C/4S/E6AP/ p53-core ternary complex structure suggested that the E6-p53 interface can be subdivided into three regions [10, 32] . E6 F47R 4C/4S residues at subinterface I include: Met1-Arg8, Arg10, Lys11, Gln14 and Glu18; at subinterface II Ile23, His24, Tyr43, Asp44, Phe47 and Asp49, and at sub-interface III; Leu100 and Pro112. The E18A/R point mutation of E6 impaired E6/E6AP/p53 ternary complex assembly, while D44R and D49A substitutions hindered p53 degradation in addition to complex assembly [10] . After addition of the Cu 2+ complex (Figs 4H,I and 5), the NMR intensity of these interface residues revealed almost complete signal loss for Glu18, Asp44 and Asp49 and significant intensity decreases for Glu7, Arg8, Arg10, Ile23 and R47 (marked red in Fig. 4H,I ), while residues Met1-Gln6, Lys11, Gln14, His24, Tyr43 and Leu100 remain almost unaffected. NMR intensities decreased for those residues, which are in close proximity to the paramagnetic Cu 2+ moiety, because of paramagnetic relaxation enhancement [19, 29] .
E6 possesses a conserved LxxLL binding pocket formed by residues from the N-and C-terminal domains (denoted as E6N and E6C in Fig. 4I ) also harbouring the Zn-binding site and the linking helix. Val31, Tyr32, Leu50, Cys51, Val53, Val62, Leu67, Tyr70, Ile73 and Leu100 of E6 contribute to the LxxLL binding pocket [10, 11] . NMR titration shows that the intensities of Val31, Leu50, Cys51, Val53 and Ile73 are significantly reduced upon addition of the Cu 2+ complex (marked in magenta in Fig. 4H,I ). Thus, various key residues in the N-terminal domain of E6 F47R 4C/4S indicate that the Cu 2+ complex can compete with p53 and E6AP binding. In addition, the NMR titration analysis of the whole E6 F47R 4C/ 4S sequence showed that the intensity of many other residues from both the N-and C-terminal domain significantly decreased (Fig. 5) . We anticipate that the local unfolding [43] of E6 F47R 4C/4S upon Cu 2+ complex binding detected by CD spectroscopy might correspond to these residues, which are then responsible for inducing E6 F47R 4C/4S aggregation. 
Discussion
Gardasil and Cervarix are the marketed HPV vaccines offering preventive care to uninfected humans [44, 45] . However, at present, therapeutic treatments are not available to infected individuals. Additionally, these vaccines are expensive and the overall 5 year treatment rate is~90% for cervical cancer, reducing sharply to 15% if the cancer has spread to other organs (according to the American Cancer Society). We demonstrated that a complex of Cu 2+ and anthracenylterpyridine showed sub-micro-molar inhibition of various cervical cancer cell lines. Their IC 50 values showed a clear dependency on the number of HPV copies present in the cancer cell lines and exhibited granulated structures inside cells. We proposed that the Cu 2+ complex induces aggregation of HPV-E6 inside cells, eventually causing apoptosis of HVP-infected cells [23] . As p53 expression levels are quite low in HPV-containing tumour cells, due to E6-directed degradation, many therapeutic strategies have been focused on blocking E6 function, thereby stabilizing p53. An increase in the cellular p53 level and concomitant suppression of tumour growth has been achieved in both tissue culture and animal models using RNAi or antisense oligodeoxy-nucleotides [46, 47] . Recently reported crystal structures of the ternary complex [10] suggested that another approach is to disrupt the interactions of the E6-E6AP or E6-p53 heterodimer, inducing cell cycle arrest or apoptosis by increasing p53 levels in the infected cells. Several inhibitors such as Pitx2a protein inhibitor [48] , a-helical peptides [49, 50] and intrabodies [51] have been developed, however, all of these show modest activity. An alternate way is to develop small molecules which exhibit the unique phenomenon of nullifying the E6 hijacking function and thus stabilizing the cellular p53 level. The Cu 2+ complex described in the present study exhibits these features by aggregating E6 and stabilizing cellular levels of p53.
We tested various other small molecules (such as acid fuchsin, acridine orange, fast green FCF, benzimidazole, thioflavin T., vanillin etc.) to determine whether or not they can induce E6 F47R 4C/4S aggregation under in vitro conditions. None of these generated observable E6 F47R 4C/4S aggregates. Additionally, previous studies about inhibitors developed to disrupt the E6 ternary complex, never reported aggregation of E6 under any of the experimental conditions tested. These studies include a high throughput screen of flavonoids disrupting HPV-16 E6 function [16] , the screening of over 88 000 diverse small molecules as HPV E6 inhibitors [17] , the small inhibitory peptides [18] , chimeric proteins [52] , the Pitx2a protein inhibitor [48] , a-helical peptides [49, 50] , and intrabodies [51] to name but a few. We also tested whether the Cu 2+ complex induces aggregation of proteins other than E6 F47R 4C/4S. Although we chose a diverse set of proteins including Kti11, a protein which coordinates Zn 2+ through four cysteine residues [42] , or a disulfide bond-rich protein (HSA), none showed formation of welldefined spherical aggregates. Therefore, we anticipate that inducing the E6 F47R 4C/4S aggregation phenomenon by the Cu 2+ complex is rather specific. The aggregates formed by coincubation of E6 F47R 4C/4S and the Cu 2+ complex are well-defined, round in shape and amorphous in nature. FCS, electron microscopy and DLS analyses suggest a gradual increase in the size of the aggregates with time up to 1 lm in diameter. The proteinaceous nature of the aggregate was confirmed by SDS/PAGE. An NMR titration with the Cu 2+ complex revealed the E6 F47R 4C/4S residues sense binding (Fig. 5) . In vitro dimerization of E6 occurs via the N-terminal domain [32] and the majority of residues at the dimer interface (Ile23, Arg39, Tyr43, Asp44, Ala46 and Phe47) are also involved in Cu 2+ binding (Fig. 5A ). Note that Phe47 was mutated to Arg in E6 F47R 4C/4S to increase the solubility and that mutations of the dimer interface disrupt E6 self-association and inactivate E6-mediated p53 degradation [32] . We suggest that the Cu 2+ complex overrides the solubility promotion of Arg47 leading to E6 aggregates. We cannot distinguish from the data presented here whether disruption of the dimerization or the loss of soluble E6 protein, increases p53 levels in vivo upon incubation with the Cu 2+ complex. Also, we are unable to rule out the possibility that the Cu 2+ complex may interact with other cellular proteins.
E6 F47R 4C/4S binds two Cu 2+ complexes with micromolar affinity (K d = 1 lM). Several residues affected by this binding are also involved in E6AP and p53 binding (Fig. 4H,I ). Additionally, Cu-perchlorate or 9-anthracene methanol could not establish such residue-specific interactions. Therefore, we propose that the Cu 2+ complex can compete with p53 hijacking given that the in vitro K d between E6 F47R 4C/4S and the p53 core is within the same range (22 lM according to [10] ). Additionally, the Cu 2+ complex interacts with four residues of E6 F47R 4C/ 4S (V32, L50, V53, I73), which facilitate E6AP binding (Fig. 4H,I ). Again we propose that a competition with E6AP is feasible because the E6 F47R 4C/4S/ E6AP interaction is in the low micromolar range [18] . In summary, we have shown the aggregation of HPV oncoprotein E6 in vitro and inside cells, and that this phenomenon is exclusively induced by the Cu 2+ complex, leading to increased p53 levels thereby shortening life-time of HPV-infected cells by inducing apoptosis. We anticipate that the Cu 2+ complex described here might lead to the development of drugs which specifically target E6 in cancer cells and combat HPVmediated infections.
Experimental section
Protein expression and purification
The plasmid corresponding to the DNA sequences of HVP 16 E6 F47R E6 4C/4S was cloned in the NcoI and KpnI sites of the pETM-41 vector containing an N-terminal His 6 -MBP tag followed by a TEV cleavage site. This plasmid was provided by Gilles Trav e, IGBMC, France. F47R E6 4C/4S was purified following the previously reported method [32] . In brief, pETM-41 carrying the gene of F47R E6 4C/4S was transformed into the Escherichia coli BL21 (DE3) cells containing kanamycin as the selection antibiotic. These cells were grown in Luria-Bertani media at 37°C followed by induction with IPTG and further growth for 17 h at 15°C. The MBP-E6 F47R 4C/4S was purified from the soluble fraction using amylose affinity chromatography. The fused protein was cleaved by TEV protease and further purified by S75 gel filtration chromatography. The purity of the protein was analysed on 12% SDS/PAGE.
Protein aggregation and electron microscopy E6 F47R 4C/4S and Cu 2+ complex were mixed in a 1 : 2 ratio (20 : 40 lM) and incubated at room temperature in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT. Samples were taken out at 0, 30, 60, 120, 180, 240, 300 and 360 min. EM grids were immediately prepared by pipetting the mixture onto a Formvar carboncoated copper grid. The grids were washed and stained with 25 lL of 2% (w/v) uranyl acetate. The grids were examined using a Zeiss 900 transmission electron microscope (Carl Zeiss Promenade, Jena, Germany) operated at an acceleration voltage of 80 kV. The Cu 2+ complex was dissolved in dimethyl sulfoxide (DMSO) and further diluted for experiments. The final concentration of DMSO was < 1% in any experiment. The small molecule screening was performed in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT. In these experiments E6 F47R 4C/4S and small molecule were mixed in a 1 : 2 ratio of protein : small molecules (20 : 40 lM). The protein screening was carried out in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT. Here, the protein solution was mixed with the Cu 2+ complex in a 1 : 2 mol : mol ratio (protein : Cu 2+ complex). The mixture was incubated at room temperature for 6 h and EM grids were prepared as described above.
Fluorescence correlation spectroscopy
Two of the E6 F47R 4C/4S cysteines are available to be labelled using maleimide chemistry. These two cysteine residues in E6 F47R 4C/4S allow site-specific derivatization using a sulfhydryl reactive fluorophore (Alexa 
Fluorescence spectroscopy
The fluorescence experiments were carried out in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT at 5 lM E6 F47R 4C/4S on a Jasco FP6500. The samples were excited at 280 nm. In a titration experiment, 4 lM of Cu 2+ complex was added and spectra were recorded after each addition. A blank titration was used as reference, using Cu 2+ complex alone in buffer, and these spectral traces were subtracted from the main titration data.
Fluorescence data were analysed according to the following equation:
with
and Q -fluorescence intensity, P -protein concentration, L -ligand concentration, V -volume, n -binding sites and subscript 0 -indicates start point.
CD spectroscopy
CD titration experiments were carried out in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT at 15 lM E6 F47R 4C/4S. In a titration experiment 10 lM of the Cu 2+ complex was added at each time.
Final spectra represented are the average of four successive scans. A blank titration containing only the Cu 2+ complex was subtracted from the spectra from the main titration experiment. CD spectra were recorded on a Jasco-J810 spectropolarimeter with a scan speed of 20 nmÁmin À1 using 1 mm path length cuvette.
Dynamic light scattering (DLS)
A 1 : 2 ratio (20 : 40 lM) of E6 F47R 4C/4S and Cu 2+ complex were mixed and incubated at room temperature in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT for 6 h. Cu 2+ -perchlorate or 9-anthracene methanol were also incubated under the same conditions. After 6 h incubation time, 300 lL samples were injected into a Wyatt miniDawnTreos Ò (Wyatt Technology Corporation, Santa Barbara, CA, USA) system (equipped with an additional DLS detector). Filtered (0.22 lm) and degassed buffer was used to obtain 5 min baselines before and after sample injection. The flow cell was cleaned after each run using 1 mL of 1 M nitric acid followed by 2 mL each of H 2 O and buffer. Data analysis was performed on a 3 min sample window using ASTRA 6.0.3 software by the methods of regularization [53] and cumulants analysis [54] . Cumulants analysis provided the Z-average radius (z) and standard deviation (r) of the solution [54] . The PDI was calculated using the following equation:
Nanoparticle tracking analysis (NTA) complex was added until no further changes in cross-peak intensities were observed. NMR spectra were recorded with a Bruker 800 MHz Avance III spectrometer equipped with a CP-TCI cryoprobe at 25°C. Spectra were processed using the programs NMRPipe and NMR Draw. The spectrum corresponding to the 1 : 2 ratio of E6 F47R 4C/4S to Cu 2+ complex was analysed. Previously assigned NMR resonances [32] were used for data analysis. Cu 2+ -perchlorate or 9-anthracene methanol was mixed with E6 F47R 4C/4S at 1 : 2 ratio and spectrum was recorded as described above.
Cell culture
Cervical carcinoma cells (HeLa) and breast cancer cells (MCF-7) were cultured in Dulbecco's modified Eagle's medium, whilst CaSki (cervical carcinoma cells) were cultured in RPMI media supplemented with 10% heat inactivated (56°C for 30 min; FBS at 37°C in a humidified chamber with 5% CO 2 .
Cell viability assay
Cell viability was determined by a MTT assay. HeLa, MCF-7 or transfected MCF-7 cells were co-incubated with increasing amounts of the Cu 2+ complex (0-15 lM). After 48 h of incubation, 50 lL of MTT (1 mgÁmL À1 ) was added and further incubated for 4 h at 37°C. Thereafter, 100 lL of DMSO was added and absorbance was recorded at 570 nm using 630 nm as a reference filter. The cells measured without the Cu 2+ complex were considered as having 100% cell viability. The experiments were performed in triplicates and repeated three times. In the control experiment cells were treated with 15 lM of Cu 2+ -perchlorate or 9-anthracene methanol. For nuclear fragmentation experiments cells were tested at IC 50 (HeLa and CaSki cells at 1 lM and MCF-7 cells at 6 lM) and incubated for 48 h.
Transfection experiment
The MCF-7 cells were transfected by Lipofectamine2000 (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's instructions. Semiconfluent (80-90%) MCF-7 cells were transfected with 2 lg of pFLAG-GFP-E6 F47R 4C/4S. As an internal control, 0.5 lg of pEGFPC1 plasmid was added to assess the transfection efficiency. The final DNA amount was adjusted to 6 lg using the pCDNA plasmid as carrier DNA. This DNA mixture was added to Lipofectamine2000 (diluted Opti-MEM medium). This mixture was incubated at room temperature for 45 min to allow Lipofectamine2000-DNA complex formation. The Lipofectamine2000-DNA complex was added drop wise to the MCF-7 cells and mixed gently.
Western blot analysis
For the western blot analysis, the cells were treated at the IC 50 concentration (HeLa and CaSki cells at 1 lM and transfected MCF-7 cells at 2 lM) and incubated for 48 h. Cells were washed with ice cold phosphate buffered saline and lysed with lysis buffer (50 mM Tris-Cl, pH 7.5, with 120 mM NaCl, 10 mM NaF, 10 mM sodium pyrophosphate, 2 mM EDTA, 1 mM Na 3 VO 4 , 1 mM PMSF, 1% NP-40 and protease inhibitor cocktail). Fifty lg of heated proteins (95°C for 10 min) in 19 SDS/loading buffer [50 mM TrisCl (pH 6.8), 2.5% b-mercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% glycerol] was resolved on SDS/PAGE. The proteins were transferred onto a nitrocellulose membrane. The cut strips of membrane corresponding with the appropriate protein size, e.g., E6/E6 F47R 4C/4S 19 kDa, GFP-E6 F47R 4C/4S~46 kDa, p53~43 kDa and (GAPDH)~35 kDa, were washed and incubated with 1 : 1000 dilutions of E6, GFP, p53 or GAPDH antibodies, respectively. After washing, the membranes were then incubated with 1 : 2000 dilutions of HRP-linked secondary antibodies. The HRP activity was detected by chemiluminescence. In these experiments, GAPDH served as loading control. The antibodies were purchased from AbCam, Cambridge, UK.
supported by grants from the DFG (GRK 1026, SFB TRR102), the BMBF (ProNet-T3), the state SachsenAnhalt (Exzellenznetzwerk Biowissenschaften), and ERDF by the EU.
